Julie Johnson
Trade Performance Intelligence
Score: 6/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
2 flagsThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
DeOndra Dixon INCLUDE Project Act of 2025
The DeOndra Dixon INCLUDE Project Act of 2025 (HR3491) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill authorizes the NIH to establish a dedicated program for Down syndrome research, which could increase demand for genetic sequencing, diagnostic services, and pharmaceutical development. While the bill does not appropriate funds, it sets the framework for future funding opportunities.
PFAS–Free Procurement Act of 2025
The PFAS-Free Procurement Act of 2025 (HR3110) is in early legislative stages, aiming to prohibit federal agencies from purchasing certain items containing PFOS or PFOA. While $MMM and $DD have exposure to PFAS-related products, their recent stock performance shows mixed trends, with $MMM down 7.5% over 30 days and $DD down 2.46% over 30 days, suggesting broader market factors are currently more dominant than this early-stage bill.
Intelligence Authorization Act for Fiscal Year 2026
The Intelligence Authorization Act for Fiscal Year 2026, S. 2342, authorizes appropriations for intelligence activities, indicating increased future demand for defense and technology contractors. This bill, reported by Senator Cotton from the Select Committee on Intelligence, is currently on the Senate Legislative Calendar, signaling active legislative momentum. While the bill authorizes spending ceilings, actual funding will depend on subsequent appropriations.
To amend title 23, United States Code, and the Infrastructure Investment and Jobs Act with respect to vehicle roadside crashes, work zone safety, and for other purposes.
HR2992, currently in the early committee stage, aims to enhance roadside and work zone safety through expanded data collection and public awareness. While the bill does not authorize direct funding, it could create future demand for safety equipment and vehicle technology. The presence of a related Senate bill, S3871, indicates bipartisan interest in the issue.
Fight Illicit Pill Presses Act
The Fight Illicit Pill Presses Act, S2870, is an early-stage bill that expands the definition of 'regulated persons' under the Controlled Substances Act to include manufacturers, distributors, and brokers of tableting and encapsulating machines and their critical parts. This legislation increases regulatory burdens and compliance costs for industrial machinery producers. The bill has a companion in the House, HR5880, indicating broader legislative interest.
Medical Research for Our Troops Act
The 'Medical Research for Our Troops Act' (HR3906) proposes to restore $1.181 billion to the Defense Health Agency for military health R&D. This bill is in the early stages, having been referred to the House Committee on Appropriations on June 11, 2025. Companies with defense contracts in clinical research, medical devices, and pharmaceuticals would benefit if this funding is restored.
Medicare for All Act
The Medicare for All Act (HR3069) has been introduced in the House and referred to seven committees. This bill proposes a national health insurance program that would eliminate private health insurance and shift all healthcare spending to the federal government, directly impacting the business models of private health insurers and potentially reducing pricing power for pharmaceutical and medical device companies. Despite the bill's early stage, its comprehensive scope represents a significant long-term risk to the healthcare sector.
BUST FENTANYL Act
The BUST FENTANYL Act (S860) has advanced to the Senate Legislative Calendar, indicating continued legislative momentum. This bill mandates intelligence and diplomatic actions to identify foreign opioid traffickers, prioritizing Chinese nationals, which increases demand for data analytics and intelligence support services. No new funds are appropriated by this bill, meaning any increased demand for services would need to be covered by existing agency budgets or future appropriations.
LAST ACRE Act of 2025
The LAST ACRE Act of 2025 establishes a new USDA grant and loan program to fund broadband and wireless connectivity on active agricultural land. This creates a new market for telecommunications infrastructure and services, directly benefiting providers and agricultural technology companies. The bill mandates funding for broadband to structures and devices, and wireless connectivity for data transmission, driving demand for rural network expansion.
Live Charts
Other Filings by Julie Johnson
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.